Q-omics provides the consensus-scored LNC-LBCS profile across patient tissues and cancer cell-line models. LNC-LBCS expression is associated with patient survival in 23 of 34 cancer types, with the highest sampling consensus in KIRC. Among the 18 cancer types available for tumor–normal comparison, LNC-LBCS is differentially expressed in 13, with the highest sampling consensus in KICH. Additionally, LNC-LBCS RNA expression shows 13,899 significant gene co-expression associations, with the highest sampling consensus in TGCT. Together, these results highlight KIRC, KICH, and TGCT as cancer lineages where LNC-LBCS shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for LNC-LBCS — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes LNC-LBCS survival associations across molecular data types. LNC-LBCS RNA expression shows survival associations in the most cancer types (23). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible LNC-LBCS RNA expression–survival associations across cancer types. High LNC-LBCS expression shows unfavorable associations in HNSC, but favorable associations in KIRC, OV, LUSC, SKCM and UCEC. The KIRC Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify KIRC as the clearest survival context for LNC-LBCS RNA expression.
This table summarizes LNC-LBCS tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 13. The strongest signals are observed in KICH for RNA.
This table ranks reproducible tumor–normal expression differences for LNC-LBCS. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. LNC-LBCS shows lower tumor expression in KICH, LUAD, KIRC, THCA and LUSC and higher tumor expression in COAD. The KICH box plot shows higher LNC-LBCS RNA expression in normal versus tumor tissue (log2 FC = −1.458, t-test p < 0.001).
This table shows molecular features associated with LNC-LBCS in patient tissues and cancer cell lines. In patient samples, LNC-LBCS shows the broadest associations at the RNA and protein expression levels, with TGCT recurring as the lineage with the largest associated feature set.
